Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06639542
Recruiting Observational

Sexual Agency of Women Who Have Suffered from Incest(s)

NCT06639542 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-10-14
Last updated
2024-10-15

Condition(s) studied

Rape Sexual AssaultIncestAssaultViolence Against WomenTherapy

Study summary

Case study, qualitative and exploratory approach with prospective research. This study is aimed at voluntary patients referred by the women center.

* The first meeting will be the presentation of a sexo-psychomotor questionnaire, specifically made for this study. Then, if the participant is willing, the enroll for a psychomotor follow-up of 6 sessions personalized with specific objectives defined for the patient,from the questionnaire.
* These therapy sessions can be renewed in discussion with the woman if we feel they would benefit from further follow-up. The psychomotor sessions last around 45 minutes and take place once every 15 days or 3 weeks with a variety of therapeutical techniques. This interval between sessions allows time for integration of the aspects addressed during the proposals, while ensuring continuity in the follow-up. They are aimed at developing body and emotional awareness, to help patients get to know themselves better, and experience moments in full awareness
* End-of-follow interview with taking the questionnaire a second time, to determine, with the woman, any benefits of the "sex-psychomotor" care. The women will be supported in completing the questionnaire again, as they were during the initial session.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \> 18 years old * Women who have suffered from incest or rape * Speak and understand French Exclusion Criteria: * Refusal to participate * Non french-speakers

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maison des femmes Saint-Denis Seine Saint Denis Recruiting

More Centre Hospitalier de Saint-Denis trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06639542 on ClinicalTrials.gov ↗ ← All trials in France